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Background: The insulin-like growth factor (IGF) pathway is implicated in the pathogenesis of hepatocellular
carcinoma (HCC) and may be important in nonalcoholic fatty liver disease (NAFLD). The aim of this study is to
determine expression levels of IGFs and receptors in NAFLD-associated HCC.
Methods: Tissue microarrays were constructed from patients who underwent hepatectomy for HCC.
Immunohistochemistry was performed using antibodies for IGF ligands and receptors. Immunostain results were
scored by a pathologist blinded to clinical data.
Results: Among 27 patients with HCC, the most common underlying liver diseases included NAFLD, hepatitis C,
and alcoholic hepatitis. Expression levels of IGFs and receptors were not associated with patients’ underlying liver
disease. In all patients, IGF-2 expression was upregulated in tumor and adjacent non-neoplastic liver. Expression of
IGF-1 was low in adjacent liver in 6 of 10 patients with cirrhosis, compared with 2 of 17 patients without cirrhosis
(P = 0.025). Higher IGF-1 expression in liver adjacent to tumor was associated with poorer median survival of
22 months, compared with 72 months with equal or lower IGF-1 expression in adjacent liver relative to tumor
(P = 0.006).
Conclusions: Our preliminary results demonstrate significant associations between IGF-1 expression and liver
cirrhosis and survival after resection in patients with HCC, independent of their underlying liver disease.
Keywords: hepatocellular carcinoma, insulin-like growth factor, nonalcoholic fatty liver diseaseBackground
Hepatocellular carcinoma (HCC) is the fifth most preva-
lent cancer worldwide and the fastest growing cause of
cancer-related death in the United States male popula-
tion [1]. Nonalcoholic fatty liver disease (NAFLD) is
increasingly recognized as a growing cause of nonalco-
holic steatohepatitis, progressing to cirrhosis and HCC.
Alarmingly, NAFLD may directly promote hepatocarci-
nogenesis independent of steatohepatitis or cirrhosis [2].
In addition, NAFLD may exert synergistic effects with
viral hepatitis in the development of HCC [3]. Nonalco-
holic fatty liver disease is the major hepatic manifest-
ation of the metabolic syndrome, marked by obesity,* Correspondence: ys475@yahoo.com
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unless otherwise stated.type 2 diabetes, hypertension, or hyperlipidemia. Popu-
lation studies demonstrate a 90% increased risk of HCC
in the obese, while type 2 diabetes confers a three-fold
increased risk [4,5]. Both NAFLD and associated HCC
are growing public health concerns, owing to the epi-
demic of obesity in the United States, with nearly two-
thirds of the adult population classified as overweight
or obese [6,7].
The molecular basis for the transformation of NAFLD
into HCC is poorly understood. Previous studies have
demonstrated that the insulin-like growth factor (IGF)
signal transduction pathway is activated early in up to
90% of HCC and may be particularly important in pa-
tients with the metabolic syndrome and NAFLD [8]. The
hallmark of the metabolic syndrome is insulin resistance,
and the resultant hyperinsulinemia leads to decreased
concentrations of IGF binding proteins and increasedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathologic factors in 27 patients
undergoing resection of hepatocellular carcinoma
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[9]. In addition, plasma levels of insulin-like growth
factor-2 (IGF-2) are increased in obese and type 2 dia-
betic patients [10]. Signaling through the insulin and
IGF-1 receptors has been shown to increase cellular pro-
liferation, inhibit apoptosis, and promote metastasis.
The IGF pathway is composed of ligands, receptors,
substrates, and ligand binding proteins (Figure 1) [11,12].
The ligands are insulin, IGF-1, and IGF-2. Insulin-like
growth factor-1, produced mainly in the liver, circulates as
an endocrine hormone but is also synthesized in target tis-
sues, where it works in a paracrine or autocrine fashion.
Insulin-like growth factor-2 is highly expressed in fetal
liver but rapidly downregulated after birth, and its physio-
logic function in adult liver remains obscure. The IGF-1
receptor (IGF-1R) is a tyrosine kinase cell-surface receptor
that is activated by IGF-1 and IGF-2, and by insulin at a
much lower affinity. Signaling via IGF-1R leads to phos-
phorylation of insulin receptor substrate and Src hom-
ology 2 domain-containing transforming protein 1 (SHC).
Phosphorylation of these receptor substrates results in ac-
tivation of the phosphatidylinositide 3-kinase/Akt (PI3K/
Akt) and mitogen-activated protein kinase (MAPK) signal-
ing cascades and plays a key role in promoting malignant
transformation of many cancers, including breast, colon,
and lung cancer. The insulin-like growth factor-2 receptor
(IGF-2R) lacks a tyrosine kinase domain and acts as aFigure 1 Insulin-like growth factor pathway. Bioavailability of the
ligands IGF-1 and IGF-2 is regulated by IGF binding proteins. The
insulin receptor and IGF-1R are tyrosine kinase cell-surface receptors
that recruit and phosphorylate adaptor proteins belonging to the
insulin receptor substrate or SHC family, leading to activation of the
PI3K/Akt and MAPK signaling cascades. IGF-2R lacks an intracellular
tyrosine kinase domain and leads to IGF-2 degradation. IGF-1,
insulin-like growth factor-1; IGF-1R, insulin-like growth factor-1
receptor; IGF-2, insulin-like growth factor-2; IGF-2R, insulin-like
growth factor-2 receptor; IRS, insulin receptor substrate; MAPK,
mitogen-activated protein kinase; P13K/Akt, phosphatidylinositide
3-kinase/Akt; SHC, Src homology 2 domain-containing transforming protein 1.
No 22
Maximum tumor size > 5 cm
Yes 14
No 13
Preoperative median serum α-fetoprotein level (range) 6 (1 to 8122)
Preoperative median Model for End-Stage Liver
Disease score (range)







Minor (resection of <3 segments) 22
Major (resection of ≥3 segments) 5





aOther diagnoses were fibrolamellar carcinoma, clear cell carcinoma,
and hemochromatosis.
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ation. This receptor has low affinity for IGF-1 and does
not bind insulin [13].
This study sought to determine expression levels of
IGFs and their receptors in patients with HCC associ-
ated with NAFLD and other underlying liver diseases.
We hypothesized that patients with NAFLD-related
HCC have alterations in the IGF pathway that are dis-
tinct from those in patients with HCC from other
causes, such as viral and alcoholic hepatitis. Identifica-
tion of upregulated components of the IGF pathway
may have potential therapeutic implications for patients
who may benefit from treatment with IGF-1R inhibi-




Formalin-fixed, paraffin-embedded blocks from patients
who underwent liver resection for HCC at Fox Chase
Cancer Center (Philadelphia, PA, USA) were used to con-
struct tissue microarrays. Areas containing viable tumor
cells and adjacent non-neoplastic liver parenchyma >1 cm
from the tumor margin were marked by a pathologist.
Three 1.0-mm cores were taken from tumor and non-
neoplastic tissue and arrayed on a paraffin block.
Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed [14,15]. Briefly, after deparaffinization and rehy-
dration, tissue sections (5 μm thick) were subjected to
antigen retrieval, followed by peroxidase block and treat-
ment with a blocking reagent for nonspecific binding.
The slides were then incubated overnight with primary
antibody at 4°C in a humidified chamber. The follow-
ing primary antibodies were used: IGF-1 (Santa Cruz
Biotechnology, Santa Cruz, CA, dilution 1:100), IGF-2
(Abcam, Cambridge, MA, 1:500), IGF-1R (Cell Signaling,
Danvers, MA, 1:50), and IGF-2R (Cell Signaling, 1:50);
followed by peroxidase-conjugated secondary antibody.
Normal kidney served as positive controls for IGF-1,
IGF-1R, and IGF-2. Negative controls included omission
of primary antibody.Table 2 Proportion of patients with positive immunohistoche
stratified by underlying liver disease
Nonalcoholic fatty liver disease Hepatitis C Alcoholi
IGF-1 8/13 6/7 1/2
IGF-1R 0/13 1/7 1/2
IGF-2 13/13 7/7 2/2
IGF-2R 6/13 3/7 1/2
aOne patient each with fibrolamellar carcinoma, clear cell carcinoma, and hemochro
positive staining.All immunohistochemistry evaluation was performed
in a blinded manner by an attending pathologist. The
slides were scored semiquantitatively. A score of 0 indi-
cated no staining, 1 indicated focal weak staining, 2 indi-
cated moderately positive staining, and 3 indicated
intensely positive staining. Tumors with strong staining
(scores 2 to 3) were grouped, and tumors with weak or
no staining (scores 0 to 1) were grouped. All analyses
were performed in triplicate.
Correlation with clinicopathologic factors
Electronic medical records of 27 patients who under-
went liver resection for HCC between 1994 and 2011
were reviewed. Patients were diagnosed with NAFLD-
associated HCC if they did not have a history of alcohol
abuse or viral hepatitis, had features of the metabolic
syndrome, such as diabetes, hyperlipidemia, or hyper-
tension, and had evidence of hepatic steatosis on patho-
logic examination. Tumors were staged after resection
according to the 7th edition of the American Joint
Committee on Cancer Staging Manual [16]. This study
was approved by the Fox Chase Cancer Center Institu-
tional Review Board, which waived the requirement for
informed consent.
Statistical analysis
Categorical variables were compared using Fisher’s exact
test. Continuous data were expressed as the median
and range and compared using the Mann-Whitney test.
Survival analysis was performed using the Kaplan-Meier
method, and differences in survival were compared using
the log-rank test. Factors significant in univariate ana-
lysis (P < 0.05) were entered into multivariate analysis,
performed using the Cox proportional-hazards model.
All statistical tests were two-sided; the significance par-
ameter was set at P < 0.05. Statistical analysis was per-
formed using SPSS software, version 17.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
Clinicopathologic factors of the 27 patients who under-
went resection of HCC are depicted in Table 1. Medianmical staining in hepatocellular carcinoma tumor tissues
c hepatitis Transformed adenoma Othera P
2/2 3/3 0.418
1/2 0/3 0.085
2/2 3/3 Not applicable
1/2 2/3 0.972
matosis. Positive staining was defined as moderately or intensely
Table 3 Proportion of patients with positive immunohistochemical staining in adjacent non-neoplastic liver stratified
by underlying liver disease
Nonalcoholic fatty liver disease Hepatitis C Alcoholic hepatitis Transformed adenoma Othera P
IGF-1 8/13 4/7 2/2 2/2 3/3 0.403
IGF-1R 0/13 0/7 1/2 0/2 0/3 0.011
IGF-2 13/13 7/7 2/2 2/2 3/3 Not applicable
IGF-2R 6/13 2/7 2/2 2/2 3/3 0.087
aOne patient each with fibrolamellar carcinoma, clear cell carcinoma, and hemochromatosis. Positive staining was defined as moderately or intensely
positive staining.
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patient died from postoperative complications.
Expression levels of IGFs and their receptors were not
associated with patients’ underlying liver disease, with
the exception of IGF-1R (Tables 2 and 3). In HCC tumor
samples, IGF-1R expression was low in 24 of 27 patients.
In adjacent noncancerous liver, IGF-1R was strongly
expressed in only one patient with alcoholic hepatitis.
Intense immunoreactivity was observed for IGF-2 in all
paired samples of tumor and background liver.
Associations between clinicopathologic factors and expression
of IGF ligands and receptors in HCC tumor samples
The HCC expression of IGF-2R was significantly higher
in men, with strong staining in 10 of 14 men versus 3 of
13 women (P = 0.021). Expression levels of IGFs and
their receptors in HCC were not associated with patient
age, American Joint Committee on Cancer stage, tumor
size, number, grade, serum α-fetoprotein concentration,
Model for End-Stage Liver Disease score, or the pres-
ence of vascular invasion (all P > 0.05).
Associations between clinicopathologic factors and
expression of IGF ligands and receptors in paired samples
of adjacent non-neoplastic liver
Expression of IGF-1 was low in non-neoplastic liver in 6
of 10 patients with cirrhosis, compared with 2 of 17 pa-
tients without cirrhosis (P = 0.025, Figure 2).Figure 2 Representative IGF-1 expression in hepatocellular
carcinoma. Immunohistochemical staining in a patient with
cirrhosis showing higher IGF-1 expression in (a) hepatocellular
carcinoma compared with (b) adjacent non-neoplastic liver.
Original magnifications, 20× and 40× for (a) and (b), respectively.Expression of IGFs and their receptors in adjacent
noncancerous liver was not associated with patient age,
sex, American Joint Committee on Cancer stage, tumor
size, number, grade, serum α-fetoprotein, or the pres-
ence of vascular invasion (all P > 0.05).
Overall survival and differential IGF-1 expression in tumor
versus adjacent non-neoplastic liver
Higher IGF-1 expression in non-neoplastic liver was associ-
ated with significantly poorer median survival of 22 months
(95% confidence interval, 0 to 54 months), compared with
72 months (95% confidence interval, 37 to 107 months) with
equal or lower IGF-1 expression in adjacent liver relative to
tumor (P = 0.006, Figure 3). On multivariate analysis, higher
IGF-1 expression in adjacent noncancerous liver remained
an independent predictor of overall survival (Table 4).
Discussion
Nonalcoholic fatty liver disease is emerging as a major public
health concern in the United States, owing to its progressionFigure 3 Kaplan-Meier curves of patients with hepatocellular
carcinoma. Overall survival in 27 patients undergoing resection of
hepatocellular carcinoma was significantly lower in patients with
higher IGF-1 expression in adjacent non-neoplastic liver compared
with tumor.
Table 4 Multivariate analysis of overall survival





Yes, n = 10 56 (29 to 83)
No, n = 17 77 (27 to 127)
Vascular invasion 0.020 0.048 4.477 (1.013 to 19.789)
Yes, n = 9 30 (22 to 38)
No, n = 18 72 (43 to 101)
Multiple tumors 0.469
Yes, n = 5 56 (35 to 77)
No, n = 22 72 (12 to 132)
Size >5 cm 0.448
Yes, n = 14 31 (0 to 73)
No, n = 13 72
Underlying liver disease 0.652
Nonalcoholic fatty liver disease, n = 13 30
Hepatitis C, n = 7 77
Alcoholic hepatitis, n = 2 22
Transformed adenoma, n = 2 Not reached
Other, n = 3b 31
Sex 0.275
Male, n = 14 72 (35 to 109)
Female, n = 13 43 (26 to 60)
Age Not estimable 0.099
American Joint Committee on Cancer stage 0.212
I, n = 16 72 (8 to 136)
II, n = 8 31 (29 to 33)
III, n = 3 136
Grade 0.427
1, n = 13 72 (43 to 102)
2, n = 8 30
3, n = 4 Not estimable
Unknown, n = 2 13
Serum α-fetoprotein concentration Not estimable 0.099
Model for End-Stage Liver Disease score Not estimable 0.482
Higher IGF-1 expression in adjacent liver than tumor 0.006 0.040 7.889 (1.096 to 56.761)
Yes, n = 3 22 (0 to 54)
No, n = 24 72 (37 to 107)
aRange not estimable in all categories. bOne patient each with fibrolamellar carcinoma, clear cell carcinoma, and hemochromatosis.
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United States population and 90% of the morbidly obese
[1]. The molecular mechanisms underlying malignant
transformation in NAFLD to HCC are not well elucidated.
Dysregulation of the IGF pathway is implicated in the
pathogenesis of HCC, particularly in patients with NAFLDand the metabolic syndrome, which are associated with in-
sulin resistance, chronic hyperinsulinemia, and increased
levels of bioavailable IGF-1. In this study, expression levels
of IGF-1, IGF-2, and their receptors were determined in
paired samples of tumor and adjacent non-neoplastic liver
from patients who underwent liver resection for HCC.
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followed by hepatitis C and alcoholic hepatitis. Our pre-
liminary results demonstrate that expression levels of
IGF ligands and receptors are not associated with pa-
tients’ underlying liver disease.
In this report, IGF-1 expression in adjacent non-
neoplastic liver was low in patients with cirrhosis com-
pared with noncirrhotic patients. These results are
consistent with prior studies showing reduced serum
levels of IGF-1 in patients with hepatocellular dysfunc-
tion [17,18]. The chief stimulus for IGF-1 synthesis is
growth hormone binding to its receptors on hepatocytes,
leading to Igf1 gene transcription. In patients with
chronic liver disease, the decline in circulating IGF-1
levels is hypothesized to result from decreased func-
tional liver mass and an attenuated IGF-1 response to
growth hormone stimulation. In a recent study of 288
patients with HCC, low plasma IGF-1 levels were found
to correlate with advanced clinicopathologic parameters
and poor overall survival [19].
A key finding in this study was that higher IGF-1 ex-
pression in adjacent non-neoplastic liver than in tumor
correlated with significantly poorer survival after resec-
tion of HCC. On multivariate analysis, higher IGF-1 in
background liver and vascular invasion remained inde-
pendent predictors of worse outcome. Activation of the
IGF-1 signaling cascade leads to upregulation of down-
stream mitogens, including MAPK and PI3K/Akt. Pre-
clinical studies have identified local IGF-1 synthesis in
several cancer cell types, including HCC, leading to
autocrine and paracrine effects on cell cycle progres-
sion and inhibition of apoptosis [8,12]. Our results sup-
port the hypothesis that during hepatocarcinogenesis,
secretion of IGF-1 by adjacent hepatocytes may lead to
paracrine stimulation of HCC and more aggressive
tumor behavior.
The present data underscore the importance of IGF-2
in the pathogenesis of HCC. We found strong IGF-2
immunoreactivity in all samples of HCC and adjacent
non-neoplastic liver. Other investigators have observed
upregulation of IGF-2 in 16% to 100% of HCCs [20,21].
Consistent with our findings, Park et al. [22] identified
IGF-2 immunoreactivity in paired noncancerous liver
tissues, both at a distance from HCC tumors and in close
contact with the growing edges of tumor. In normal
adult liver, IGF-2 expression is low, and its physiologic
function is unclear. However, in hepatitis and cirrhosis,
IGF-2 expression is increased, owing to reactivation of
fetal promoters that induce Igf2 gene transcription [23].
Upregulation of IGF-2 leads to multiple oncogenic ef-
fects, including cell proliferation, anti-apoptosis, and
angiogenesis [3].
The chief limitation of this study is the small numbers
of patients, and our results require validation in a largersample population. We did not examine immunoreactivity
of insulin receptor substrates and binding proteins, which
are key components of the IGF signaling cascade. In
addition, we plan to examine downstream effects of IGF
signaling dysregulation, including effects on the PI3K and
MAPK pathways.
Conclusions
In conclusion, NAFLD was the most common under-
lying liver disease in this study of patients undergoing
resection of HCC. Expression levels of IGF ligands and
receptors did not correlate with patients’ underlying liver
disease. Others have reported overexpression of the IGF
receptors in HCC, which was not observed in the
current study, although our results should be interpreted
cautiously, owing to the small number of patients [23].
Insulin-like growth factor-2 demonstrated strong immu-
noreactivity in all patient samples of tumor and adjacent
liver, indicating the importance of IGF-2 in early and late
stages hepatocarcinogenesis. Insulin-like growth factor-1
staining was low in the background liver of cirrhotic
patients, consistent with previous literature showing low
IGF-1 levels in patients with hepatocellular dysfunction.
Patients with higher expression of IGF-1 in adjacent
liver than in tumor had significantly lower overall
survival, suggesting that increased IGF-1 synthesis by
neighboring hepatocytes may lead to aggressive tumor
biology. These results merit confirmation in a larger
number of patients and support continued investigation
of the IGF signaling cascade for potential therapeutic
targets in HCC.
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